SITC Meeting | Conference

Nivolumab/Ipilimumab Combo Is Effective, Safe in Advanced or Unresectable Angiosarcoma

November 13th 2020

November 13, 2020 - The combination of nivolumab and ipilimumab elicited an objective response rate of 25% and was found to be well tolerated in patients with advanced or unresectable angiosarcoma, according to cohort findings of the phase 2 DART trial.

STING Agonist Plus Atezolizumab Could Expand Immunotherapy Benefit to Nonresponsive Advanced Solid Tumors

November 13th 2020

November 13, 2020 - In an effort to expand the benefit of immunotherapy to nonresponders or those who have relapsed, the novel STING agonist SB 11285 is being evaluated as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors in a phase 1/1b dose-escalation trial.

Intratumoral Electroporation of pIL-12 Plus Pembrolizumab Elicits Durable Responses in PD-1–Refractory Advanced Melanoma

November 13th 2020

November 13, 2020 - The addition of plasmid IL-12 pembrolizumab resulted in durable responses, as well as several complete responses, in patients with advanced melanoma who were refractory to PD-1–directed therapy.

Dr. Campbell on the Expanding Role of Cabozantinib in RCC

November 12th 2020

Matthew T. Campbell, MD, MS, discusses the expanding role of cabozantinib in renal cell carcinoma.

Dr. Hutson on Remaining Questions With the Durability of Immune Responses in RCC

November 12th 2020

Thomas Hutson, DO, PharmD, discusses remaining questions regarding the durability of responses to immunotherapy in patients with renal cell carcinoma.

Dr. Zhang on the Combination of LAG525 and Spartalizumab in Advanced Malignancies

November 12th 2020

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

Pembrolizumab Shows Intriguing Benefit in Leptomeningeal Metastasis From Solid Tumors

November 12th 2020

November 12, 2020 — Pembrolizumab led to a 38% central nervous system response rate and was well tolerated in patients with leptomeningeal metastasis from solid tumors. However, the study was closed early due to poor accrual.

Cosibelimab Elicits Early Activity in NSCLC and Cutaneous Squamous Cell Carcinoma

November 12th 2020

November 12, 2020 - The investigational PD-L1 inhibitor cosibelimab demonstrated durable and robust responses in patients with non–small cell lung cancer and cutaneous squamous cell carcinoma.

CMP-001 Plus Pembrolizumab Elicits Deep Responses, Reverses PD-1 Resistance in Advanced Melanoma

November 12th 2020

November 12, 2020 - The combination of CMP-001 intratumoral injection and pembrolizumab was found to reverse PD-1 blockade resistance and elicit durable systemic responses in patients with advanced melanoma.

Cemiplimab Elicits Antitumor Activity in Metastatic Basal Cell Carcinoma

November 12th 2020

November 12, 2020 - Cemiplimab demonstrated clinically meaningful antitumor activity, including durable responses, and acceptable safety in patients with metastatic basal cell carcinoma after progression on or intolerance to hedgehog inhibitors

Dr. Hong Discusses IPI-549 in Advanced Solid Tumors

November 17th 2017

David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses IPI-549 during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Dr. Paulson Discusses Acquired Resistance to Immunotherapy

November 17th 2017

Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Novel Combination Shows Promising Responses in Pancreatic Cancer

November 12th 2017

The combination of cabiralizumab and nivolumab resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer.

Neoadjuvant Nivolumab/Ipilimumab Combo Effective but Toxic for Melanoma

November 12th 2017

Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.

NKTR-214/Nivolumab Combination Shows Promise in Early Study

November 12th 2017

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.

IDO Plus PD-1 Inhibitor Combo Sparks Responses in Bladder and Cervical Cancers

November 12th 2017

The combination of nivolumab and BMS-986205 generated promising response rates without increasing adverse effects in patients with advanced cervical or bladder cancers.

Dr. Luke on Combining an IDO Inhibitor With Nivolumab in Advanced Cancers

November 12th 2017

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses a study evaluating the IDO1 inhibitor BMS-986205 as a monotherapy and in combination with nivolumab in patients with advanced cancers.

Nivolumab Spurs Responses in non-CRC Patients With dMMR

November 11th 2017

Nivolumab demonstrated a 24% overall response rate among patients with a range of non-colorectal cancers with mismatch repair deficiency who were identified through the NCI-MATCH trial.

JCAR015 Experience Informs Future CAR-T Studies

November 11th 2017

The high rates of cerebral edema seen with JCAR015 in the phase II ROCKET trial were attributed to early and rapid chimeric antigen receptor (CAR)-modified T-cell expansion and a rise in interleukin-15 levels, a finding that could help inform future CAR T-cell usage.

Combinations Required to Further Advance Adoptive T-Cell Therapy

November 10th 2017

A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.